In reaching its recommendation that CanniMed shareholders vote “FOR” the
acquisition of Newstrike Resources, ISS stated:

“[CanniMed Shareholders should] vote FOR the proposed acquisition of
Newstrike, which will allow the company to access the recreational
cannabis market while also significantly expanding its production
capacity and diversifying its geographic footprint. The transaction is
expected to be accretive on a 2019 estimated EBITDA-per-share basis and
may have a positive branding impact.”

ISS also recognized that with Aurora’s hostile bid, the offer has “a
$24 offer cap that has effectively halved the exchange ratio and
CanniMed’s expected ownership stake in the combined entity… turning the
transaction into a dilutive one for CanniMed shareholders.”

Welcoming ISS’ favourable recommendation, Brent Zettl President and CEO,
CanniMed, stated: “We are pleased that ISS has recommended shareholders
vote in favour of the Newstrike acquisition. We thank our shareholders
for their ongoing support and unanimously recommend they follow the
recommendations of ISS and the Board, by voting FOR the acquisition of
Newstrike and saying NO to Aurora by not tendering and not voting on the
blue proxy.”

Shareholders are reminded every vote counts regardless of how many
shares they own and to vote their green proxies by January 19th,
2018 at 10:00 a.m. (Toronto time)

If you have any questions, please contact Kingsdale Advisors at
1-888-518-1554 toll-free in North America, or 416-867-2272 outside North
America or by email at contactus@kingsdaleadvisors.com.

About CanniMed Therapeutics Inc.

CanniMed is a Canadian-based, international plant biopharmaceutical
company and a leader in the Canadian medical cannabis industry, with 17
years of pharmaceutical cannabis cultivation experience,
state-of-the-art, GMP-compliant production process and world class
research and development platforms with a wide range of
pharmaceutical-grade cannabis products. In addition, the Company has an
active plant biotechnology research and product development program
focused on the production of plant-based materials for pharmaceutical,
agricultural and environmental applications.

CanniMed, through its subsidiaries, was the first producer to be
licensed under the Marihuana for Medical Purposes Regulations,
the predecessor to the current Access to Cannabis for Medical
Purposes Regulations. It was the sole supplier to Health Canada
under the former medical cannabis system for 13 years, and has been
producing safe and consistent medical cannabis for thousands of Canadian
patients, with no incident of product diversion or recalls.